Adiponectin Inhibits the Progression of Obesity-Associated Papillary Thyroid Carcinoma Through Autophagy
Endocrinology · 2024
DOI: 10.1210/endocr/bqae030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrinology, 2024. Verfasst von Changlin Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thyroid Surgery, China-Japan Union Hospital of Jilin University, Jilin Provincial Key Laboratory of Surgical Translational Medicine, Jili…. Hauptthemen laut MEDLINE: Carcinoma, Papillary, Thyroid Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: National Nature Science Foundation of China, Project of Jilin Provincial Finance Department.
Abstract (Originalsprache)
Context
Obesity is a risk factor for the development of papillary thyroid cancer (PTC). However, the molecular mechanisms by which obesity promotes PTC are unclear.
Objective
This study aims to identify adipokines that are linked to PTC progression.
Methods
An adipokine antibody array was used to determine the serum levels of 40 adipokines in normal-weight and obese PTC patients. Enzyme-linked immunosorbent assay was used to determine the serum levels of adiponectin. Recombinant human adiponectin was produced by human adipose-derived stem cells and used to treat PTC cells. Cell proliferation and migration were evaluated using the CCK8 and Transwell assays. Bioinformatics analysis was used to predict mechanisms by which adiponectin affects PTC.
Results
Adipokines differentially expressed between normal-weight and obese patients showed a gender-dependent pattern. Obese PTC patients had a significantly lower serum adiponectin level than normal-weight patients, especially in female individuals. Adiponectin levels were negatively correlated with aggressive features of PTC, including tumor diameter > 1 cm, extrathyroidal extension, and lymph node metastasis. Recombinant human adiponectin inhibited the proliferation and migration of human PTC cells in vitro. Bioinformatics analysis identified adiponectin receptor 2 (ADIPOR2) and the autophagy pathway as possible mediators of adiponectin function in TC. In vitro experiments confirmed that adiponectin activated autophagy in PTC cells. These findings shed new lights into the role and mechanisms of adiponectin in TC pathogenesis.
Conclusion
Adiponectin is involved in development of obesity-related PTC. Adiponectin can directly inhibit thyroid cancer growth and metastasis through the autophagy pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Thyroid Surgery, China-Japan Union Hospital of Jilin University, Jilin Provincial Key Laboratory of Surgical Translational Medicine, Jilin Provincial Engineering Laboratory of Thyroid Disease Prevention and…
- Division of Surgery, Istituto Auxologico Italiano IRCCS, 20095 Milan, Italy.
- Department of Medical Biotechnology and Translational Medicine, University of Milan, 20133 Milan, Italy.
- Department of Endocrinology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences) Southern Medical University, No. 106, Zhongshan Er Road, Guangzhou, 510080, China.
ORCID-Profile: Haixia Guan, Hui Sun
Förderung
- National Nature Science Foundation of China
- Project of Jilin Provincial Finance Department
Zitieren
APA
Li, C., Zhang, J., Dionigi, G., Liang, N., Guan, H., & Sun, H. (2024). Adiponectin Inhibits the Progression of Obesity-Associated Papillary Thyroid Carcinoma Through Autophagy. Endocrinology. https://doi.org/10.1210/endocr/bqae030
Vancouver
Li C, Zhang J, Dionigi G, Liang N, Guan H, Sun H. Adiponectin Inhibits the Progression of Obesity-Associated Papillary Thyroid Carcinoma Through Autophagy. Endocrinology. 2024. doi:10.1210/endocr/bqae030
BibTeX
@article{Li2024,
author = {Li, Changlin and Zhang, Jiao and Dionigi, Gianlorenzo and Liang, Nan and Guan, Haixia and Sun, Hui},
title = {Adiponectin Inhibits the Progression of Obesity-Associated Papillary Thyroid Carcinoma Through Autophagy},
journal = {Endocrinology},
year = {2024},
doi = {10.1210/endocr/bqae030}
}
EUVIMED